Opioid-Free Anesthesia Versus Opioid Based Anesthesia For Adolescent Idiopathic Scoliosis
Opioid-free anesthesia (OFA) is a multimodal analgesic approach designed to eliminate the intraoperative use of systemic, neuraxial, or intracavitary opioids. This technique employs a combination of antinociceptive agents targeting various pathways within the central and peripheral nervous systems to achieve effective
| Condition(s) | Opioid Free Anesthesia |
|---|---|
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional |
| Summary | Opioid-free anesthesia (OFA) is a multimodal analgesic approach designed to eliminate the intraoperative use of systemic, neuraxial, or intracavitary opioids. This technique employs a combination of antinociceptive agents targeting various pathways within the central and peripheral nervous systems to achieve effective analgesia. Dexmedetomidine (DEX), a highly selective α2-adrenoreceptor agonist, is a centrally acting non-opioid agent increasingly utilized in clinical practice for its antinociceptive and anxiolytic properties. Only a few prospective randomized controlled trials have specifically examined the postoperative analgesic efficacy of intraoperative dexmedetomidine infusion in patients undergoing spinal surgery, with limited data focusing on this as a primary endpoint. Importantly |
| Who can participate | Inclusion Criteria:Patients younger than 18 years of age, classified as American Society of Anesthesiologists (ASA) Physical Status I or II, and will be scheduled for surgical correction of adolescent idiopathic scoliosis. \- Exclusion Criteria:• Refusal to participate in the study or to allow use of personal data * Non-idiopathic scoliosis * Contraindications to commonly used perioperative medications * ASA Physical Status ≥ III * Presence of neuromuscular disorders or severe cardiac dysfunction * Requirement for postoperative mechanical ventilation * Regular use of analgesics or opioids * History of allergy to opioids or dexmedetomidine * Diagnosed mental disorders * Severe hepatic or renal dysfunction * Coagulopathy or significant pulmonary disease * Preoperative or postoperative neurol |
| Ages | 8 Years to 18 Years |
| Sex | All |
| Lead sponsor | Nashwa Ahmed |
| Locations | Port Said, Egypt |
| Start date | 2026-01-30 |
| NCT ID | NCT07389096 |
| Official listing | https://clinicaltrials.gov/study/NCT07389096 |